Number 8 labs, MB - company info and details

Company age: 5 y. 9 mo.

Update

Company overview

Company name Number 8 labs, MB
Company code 305690031
VAT code LT100016459813
Registered address Kauno r. sav., Alšėnų sen., Padainupio k., Pakalnučių g. 14, LT-53301
Registration date 2021-01-27 Company age: 5 y. 9 mo.
Phone Phone
Email Not disclosed (personal)
Website None
Revenue (2025) 41,461 € -8% History
Profit (2025) -5,192 € History
Number of employees 0
Managed vehicles 1 List
Current SODRA debt No debt Read more
Days of debt to SODRA per year 0 days
Current VMI debt No debt Read more
Financial statements All submitted
Legal form Small partnership
NACE activity Manufacture of pharmaceutical preparations
Ownership form Private without foreign capital
Public sales amount, last 12 mos. 1,621 € List

Description

This description was generated by artificial intelligence.
Number 8 labs, MB (company code 305690031) is an operational private small partnership registered on 27 January 2021. It is classified as a private company in the national private non-financial companies sector, under private ownership in which Lithuanian natural and legal persons hold more than 50% of authorised capital and no foreign investor capital is involved. Governance is classified as other, and the company is assessed as micro-sized. Its main activity is EVRK C.21.20.00, Manufacture of pharmaceutical preparations. The company is based in Kauno r. sav., Alšenu sen., Padainupio k., Kauno apskr., at Pakalnuciu g. 14, LT-53301. Financially, revenue rose from €29.6K in 2023 to €45.1K in 2024, then declined to €41.5K in 2025. Net profit improved from €348 in 2023 to €8.1K in 2024, before turning to a loss of €5.2K in 2025. The profit margin followed the same pattern, moving from 1.2% to 18.0% and then to -12.5%. At the end of 2025, equity stood at €4.9K, liabilities at €13.5K, and total assets at €18.4K.

Download a detailed company report

Make confident decisions with all the information about Number 8 labs, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.

19.99 € + PVM Get report